$NanoViricides(NNVC)$ nnvc宣称自己的药物平台不仅能够对付新冠及其变种（因结合位点不变），并且可以针对光谱的冠状病毒。
Our current drug candidates to combat the COVID-19 pandemic are designed to attack not only SARS-CoV-2 and its current and future variants, but also many other coronaviruses, and will be useful even after the pandemic is over, because several coronaviruses are endemic in human populations.
Our COVID-19 drug candidates successfully entered core safety pharmacology studies required prior to any human clinical trials around October/November, 2019. These studies have now been completed and we are anticipating the report from the external CRO shortly. We are now working on preparing a pre-IND application for filing with the US FDA as soon as possible. Additionally, we are actively seeking opportunities to engage appropriate sites for human clinical trials, and we are engaged in the preparation of clinical trial protocols and other activities that would be necessary for filing of an IND with the US FDA.